Name: methods for evaluating the role of c-fos and dusp1 in oncogene dependence
Uploaded: 2019-01-07T14:00:00
Description: Watch this Scientific Journal Video about Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence at JoVE.com

The authors are thankful to G. Q. Daley for providing the BaF3 and WEHI cells and T. Reya for the MSCV-BCR-ABL-Ires-YFP constructs. The authors are thankful to M. Carroll for providing the patient samples from the CML blast crisis. This study was supported by grants to M.A. from the NCI (1RO1CA155091), the Leukemia Research Foundation and V Foundation, and from the NHLBI (R21HL114074-01).

All animal experiments were carried out according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Cincinnati Children&#39;s Hospital Medical Center (CCHMC). Human specimens (Normal BM and that from CML (p210-BCR-ABL+) leukemia) were obtained through Institutional Review Board-approved protocols (Institutional Review Board: Federalwide Assurance #00002988 Cincinnati Children&#39;s Hospital Medical Center) and donor-informed consent from CCHMC and the University of Cincinnati.
<p class="...

<ol>
	<li>Daley, G. Q., Van Etten, R. A., Baltimore, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+chronic+myelogenous+leukemia+in+mice+by+the+P210bcr/abl+gene+of+the+Philadelphia+chromosome.">Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.</a> Science. 247, 824-830 (1990).</li><li>Druker, B. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells.">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.</a> Nature Medicine. 2, 561-566 (1996).</li><li>Mahon, F. X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Discontinuation+of+imatinib+in+patients+with+chronic+myeloid+leukaemia+who+have+maintained+complete+molecular+remission+for+at+least+2+years:+the+prospective,+multicentre+Stop+Imatinib+(STIM)+trial.">Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.</a> Lancet Oncology. 11, 1029-1035 (2010).</li><li>O'Hare, T., Zabriskie, M. S., Eiring, A. M., Deininger, M. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pushing+the+limits+of+targeted+therapy+in+chronic+myeloid+leukaemia.">Pushing the limits of targeted therapy in chronic myeloid leukaemia.</a> Nature Reviews Cancer. 12, 513-526 (2012).</li><li>Rousselot, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Imatinib+mesylate+discontinuation+in+patients+with+chronic+myelogenous+leukemia+in+complete+molecular+remission+for+more+than+2+years.">Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.</a> Blood. 109, 58-60 (2007).</li><li>Krause, D. S., Van Etten, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tyrosine+kinases+as+targets+for+cancer+therapy.">Tyrosine kinases as targets for cancer therapy.</a> The New England Journal of Medicine. 353, 172-187 (2005).</li><li>Sharma, S. V., Settleman, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Exploiting+the+balance+between+life+and+death:+targeted+cancer+therapy+and+"oncogenic+shock".">Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".</a> Biochemical Pharmacology. 80, 666-673 (2010).</li><li>Sharma, S. V., Settleman, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oncogene+addiction:+setting+the+stage+for+molecularly+targeted+cancer+therapy.">Oncogene addiction: setting the stage for molecularly targeted cancer therapy.</a> Genes &amp; Development. 21, 3214-3231 (2007).</li><li>Weinstein, I. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer.+Addiction+to+oncogenes--the+Achilles+heal+of+cancer.">Cancer. Addiction to oncogenes--the Achilles heal of cancer.</a> Science. 297, 63-64 (2002).</li><li>Corbin, A. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+chronic+myeloid+leukemia+stem+cells+are+insensitive+to+imatinib+despite+inhibition+of+BCR-ABL+activity.">Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.</a> The Journal of Clinical Investigation. 121, 396-409 (2011).</li><li>Straussman, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion.">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.</a> Nature. 487, 500-504 (2012).</li><li>Wilson, T. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Widespread+potential+for+growth-factor-driven+resistance+to+anticancer+kinase+inhibitors.">Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.</a> Nature. 487, 505-509 (2012).</li><li>Kesarwani, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeting+c-FOS+and+DUSP1+abrogates+intrinsic+resistance+to+tyrosine-kinase+inhibitor+therapy+in+BCR-ABL-induced+leukemia.">Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.</a> Nature Medicine. 23, 472-482 (2017).</li><li>Zhang, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=c-fos+regulates+neuronal+excitability+and+survival.">c-fos regulates neuronal excitability and survival.</a> Nature Genetics. 30, 416-420 (2002).</li><li>Dorfman, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disruption+of+the+erp/mkp-1+gene+does+not+affect+mouse+development:+normal+MAP+kinase+activity+in+ERP/MKP-1-deficient+fibroblasts.">Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts.</a> Oncogene. 13, 925-931 (1996).</li><li>Padhye, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fluorocurcumins+as+cyclooxygenase-2+inhibitor:+molecular+docking,+pharmacokinetics+and+tissue+distribution+in+mice.">Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice.</a> Pharmaceutical Research. 26, 2438-2445 (2009).</li><li>Molina, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Zebrafish+chemical+screening+reveals+an+inhibitor+of+Dusp6+that+expands+cardiac+cell+lineages.">Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.</a> Nature Chemical Biology. 5, 680-687 (2009).</li><li>Zhang, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effective+targeting+of+quiescent+chronic+myelogenous+leukemia+stem+cells+by+histone+deacetylase+inhibitors+in+combination+with+imatinib+mesylate.">Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.</a> Cancer Cell. 17, 427-442 (2010).</li><li>Koschmieder, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inducible+chronic+phase+of+myeloid+leukemia+with+expansion+of+hematopoietic+stem+cells+in+a+transgenic+model+of+BCR-ABL+leukemogenesis.">Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.</a> Blood. 105, 324-334 (2005).</li><li>Abraham, S. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dual+targeting+of+p53+and+c-MYC+selectively+eliminates+leukaemic+stem+cells.">Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.</a> Nature. 534, 341-346 (2016).</li><li>Li, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Activation+of+p53+by+SIRT1+inhibition+enhances+elimination+of+CML+leukemia+stem+cells+in+combination+with+imatinib.">Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.</a> Cancer Cell. 21, 266-281 (2012).</li><li>. Qiagen-miRNAeasy kit Available from: <a target="_blank" href="https://www.qiagen.com/us/shop/sample-technologies/rna/mirna/mirneasy-mini-kit/#resources">https://www.qiagen.com/us/shop/sample-technologies/rna/mirna/mirneasy-mini-kit/#resources</a> (2018)</li><li>. DNA-free DNA removal kit Available from: <a target="_blank" href="https://www.thermofisher.com/order/catalog/product/AM1906?gclid=EAIaIQobChMIg4D-_ZvC2wIVx5-zCh00Cg8fEAAYASAAEgIv6vD_BwE&amp;s_kwcid=AL!3652!3!264318446624!b!!g!!&amp;ef_id=V7SO5AAAAck3ba89:20180607185004:s">https://www.thermofisher.com/order/catalog/product/AM1906?gclid=EAIaIQobChMIg4D-_ZvC2wIVx5-zCh00Cg8fEAAYASAAEgIv6vD_BwE&amp;s_kwcid=AL!3652!3!264318446624!b!!g!!&amp;ef_id=V7SO5AAAAck3ba89:20180607185004:s</a> (2018)</li><li>. SuperScript&#8482; III First-Strand Synthesis System Available from: <a target="_blank" href="https://www.thermofisher.com/order/catalog/product/18080051">https://www.thermofisher.com/order/catalog/product/18080051</a> (2018)</li><li>. Human Long Term Culture Initiating Cell Itc-ic Assay Available from: <a target="_blank" href="https://www.stemcell.com/human-long-term-culture-initiating-cell-ltc-ic-assay.html">https://www.stemcell.com/human-long-term-culture-initiating-cell-ltc-ic-assay.html</a> (2018)</li><li>Abarrategi, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Modeling+the+human+bone+marrow+niche+in+mice:+From+host+bone+marrow+engraftment+to+bioengineering+approaches.">Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.</a> Journal of Experimental Medicine. 215, 729-743 (2018).</li><li>Kesarwani, M., Huber, E., Kincaid, Z., Azam, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+method+for+screening+and+validation+of+resistant+mutations+against+kinase+inhibitors.">A method for screening and validation of resistant mutations against kinase inhibitors.</a> Journal of Visualized Experiments. , (2014).</li></ol>

For the bulk of cancer cells, the therapeutic response to TKI is mediated by a blockade of tyrosine-kinase-oncoprotein signals to which the tumor is addicted. However, relatively little is known about how a minority of cancer cells contributing to MRD escape the oncogene dependence and therapy4. Recent studies revealed that growth factor signaling mediates drug resistance in both leukemia and solid organ tumors. This suggests that various molecular mechanisms might underlie intrinsic resistance<su...

Constitutive tyrosine kinase activity of BCR-ABL1 fusion oncogene causes CML, which provides a rationale to target the kinase activity by small molecule inhibitors. The success of TKIs in treating CML patients revolutionized the concept of targeted therapy1,2. Subsequently, anti-kinase therapy as precision medicine was developed for several other malignancies, including solid tumors. So far, more than thirty kinase inhibitors have been approved by the United State FDA for treating various malignancies. While TKI treatment is very effective in suppressing the disease, it is not curative. Besides, a small population of cancer cells persists during the treatment: the MRD3,4,5. Even patients who showed complete remission are left with MRD, which eventually results in relapse if not continuously suppressed. Therefore, the eradication of MRD cells is needed to achieve a durable or curative response. CML represents a valuable paradigm for defining the concept of precision medicine, mechanisms of oncogenesis, rational target-directed therapeutics, disease progression, and drug resistance. However, even today, the mechanism driving TKI-induced cell death in cancer cells is not fully understood, nor why MRD cells (comprised of leukemic stem cells [LSCs]) are intrinsically resistant to TKIs4,6. Nonetheless, the phenomenon of &#34;oncogene dependence&#34; to mutant kinase oncoprotein is implicated in TKI efficacy where the acute inhibition of targeted oncogene by TKIs causes an oncogenic shock that leads to a massive proapoptotic response or quiescence in cell context-dependent manner6,7,8,9. However, the mechanistic underpinning of oncogene dependence is lacking. Recent studies have implicated that growth factor signaling abrogates oncogene dependence and consequently confers resistance to TKI therapy10,11,12. Therefore, to gain insight into the mechanism of oncogene dependence, we performed whole-genome expression profiling from BCR-ABL1 addicted and nonaddicted cells (grown with growth factors), which revealed that c-Fos and Dusp1 are critical mediators of oncogene addiction13. The genetic deletion of c-Fos and Dusp1 is synthetic lethal to BCR-ABL1-expressing cells and the mice used in the experiment did not develop leukemia. Moreover, the inhibition of c-Fos and DUSP1 by small molecule inhibitors cured BCR-ABL1-induced CML in mice. The results show that the expression levels of c-Fos and Dusp1 define the apoptotic threshold in cancer cells, such that lower levels confer drug sensitivity while higher levels cause resistance to therapy13.
To identify the genes driving the oncogene dependence, we performed several whole-genome expression profiling experiments in the presence of growth factor and a TKI (imatinib) using both mouse- and CML patient-derived cells (K562). These data were analyzed in parallel with CML patient data sets obtained from CD34+ hematopoietic stem cells before and after treatment with imatinib. This analysis revealed three genes (a transcription factor [c-Fos], dual specificity phosphatase 1 [Dusp1], and an RNA-binding protein [Zfp36]) which are commonly upregulated in TKI-resistant cells. To validate the significance of these genes in conferring drug resistance, we carried out step-by-step in vitro and in vivo analysis. The expression levels of these genes were confirmed by real-time qPCR (RT-qPCR) and western blotting in drug-resistant cells. Further, cDNA overexpression and knockdown by shRNA hairpins of c-Fos, Dusp1, and Zfp36 revealed that elevated c-Fos and Dusp1 expressions are sufficient and necessary to confer TKI resistance. Therefore, we performed an in vivo validation using mouse models with c-Fos and Dusp1 only. For the genetic validation of c-Fos and Dusp1, we created ROSACreERT-inducible c-Fosfl/fl mice (conditional knockout)14 and crossed them with Dusp1-/- (straight knockout)15 to make ROSACreERT2-c-Fosfl/flDusp1-/- double-transgenic mice. Bone marrow-derived c-Kit+ cells (from c-Fosfl/fl-, Dusp1-/--, and c-Fosfl/flDusp1-/-) expressing BCR-ABL1 were analyzed in vitro in a colony-forming unit (CFU) assay, and in vivo by bone marrow transplantation in lethally irradiated mice, to test the requirement of c-Fos and Dusp1 alone or together in leukemia development. Likewise, the chemical inhibitions of c-Fos by DFC (difluorinated curcumin)16 and Dusp1 by BCI (benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one)17 were tested in vitro and in vivo using BCR-ABL1-expressing, bone marrow-derived c-Kit+ cells from the wild-type (WT) mouse. To confirm the requirement of c-Fos and Dusp1 in leukemic stem cells, we utilized a CML mouse model where BCR-ABL1 was specifically induced in its stem cells by doxycycline (Tet-transactivator expresses under murine stem cell leukemia (SCL) gene 3&#39; enhancer regulation)18,19. We used bone marrow Lin-Sca+c-Kit+ (LSK) cells from these mice in an in vivo transplant assay. Furthermore, we established phopsho-p38 levels and the expression of IL-6 as pharmaco-dynamic biomarkers for Dusp1 and c-Fos inhibition, respectively, in vivo. Finally, to extend the study for human relevance, patient-derived CD34+ cells (equivalent to the c-Kit+ cells from mice) were subjected to long-term in vitro culture-initiating cell assays (LTCIC) and an in vivo humanized mouse model of CML20,21. The immunodeficient mice were transplanted with CML CD34+ cells, followed by drug treatment and analysis of human leukemic cell survival.
In this project, we develop methods for target identification and validations using both genetic and chemical tools, using different preclinical models. These methods can be successfully applied to validate other targets developing chemical modalities for therapeutic development.

<table border="0" cellpadding="0" cellspacing="0" style="width:948px;" width="946">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:424px;">Biological Materials</td>
			<td style="width:247px;"></td>
			<td style="width:147px;"></td>
			<td style="width:131px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RPMI</td>
			<td>Cellgro (corning)</td>
			<td>15-040-CV</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DMEM</td>
			<td>Cellgro (corning)</td>
			<td>15-013-CV</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">IMDM</td>
			<td>Cellgro (corning)</td>
			<td>15-016-CVR</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RetroNectin Recombinant Human Fibronectin Fragment</td>
			<td>Takara</td>
			<td>T100B</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">MethoCult GF M3434 (Methylcellulose for Mouse CFU)</td>
			<td>Stem Cell</td>
			<td>3434</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">MethoCult H4434 Classic (Methylcellulose for Human CFU)</td>
			<td>Stem Cell</td>
			<td>4434</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">4-Hydroxytamoxifen</td>
			<td>Sigma</td>
			<td>H6278</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Recombinant Murine SCF</td>
			<td>Prospec</td>
			<td>CYT-275</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Recombinant Murine Flt3-Ligand</td>
			<td>Prospec</td>
			<td>CYT-340</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Recombinant Murine IL-6</td>
			<td>Prospec</td>
			<td>CYT-350</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Recombinant Murine IL-7</td>
			<td>Peprotech</td>
			<td>217-17</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DFC</td>
			<td>LKT Laboratories Inc.</td>
			<td>D3420</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">BCI</td>
			<td>Chemzon Scientific</td>
			<td>NZ-06-195</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Imatinib</td>
			<td>LC Laboratory</td>
			<td>I-5508</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Curcumin</td>
			<td>Sigma</td>
			<td>458-37-7</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">NDGA</td>
			<td>Sigma</td>
			<td>500-38-9</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Penn/Strep</td>
			<td>Cellgro (corning)</td>
			<td>30-002-CI</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">FBS</td>
			<td>Atlanta biological</td>
			<td>S11150</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Trypsin EDTA 1X</td>
			<td>Cellgro (corning)</td>
			<td>25-052-CI</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">1XPBS</td>
			<td>Cellgro (corning)</td>
			<td>21-040-CV</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">L-Glutamine</td>
			<td>Cellgro (corning)</td>
			<td>25-005-CL</td>
			<td style="width:131px;">5mg/ml stock in water</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Puromycin</td>
			<td>Gibco (life technologies)</td>
			<td>A11138-03</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">HEPES</td>
			<td>Sigma</td>
			<td>H7006</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Na2HPO4.7H2O</td>
			<td>Sigma</td>
			<td>S9390</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Protamine sulfate</td>
			<td>Sigma</td>
			<td>P3369</td>
			<td style="width:131px;">5mg/ml stock in water</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Trypan Blue solution (0.4%)</td>
			<td>Sigma</td>
			<td>T8154</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DMSO</td>
			<td>Cellgro (corning)</td>
			<td>25-950-CQC</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">WST-1</td>
			<td>Roche</td>
			<td>11644807001</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">0.45uM acro disc filter</td>
			<td>PALL</td>
			<td>2016-10</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">70um nylon cell stariner</td>
			<td>Becton Dickinson</td>
			<td>352350</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">FICOL (Histopaque 1083) (polysucrose)</td>
			<td>Simga</td>
			<td>1083</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">PBS</td>
			<td>Corning</td>
			<td>21040CV</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">LS Columns</td>
			<td>Miltenyi</td>
			<td>130-042-401</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Protease Inhibitor Cocktail</td>
			<td>Roche</td>
			<td>CO-RO</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Phosphatase Inhibitor Cocktail 2</td>
			<td>Sigma</td>
			<td>P5762</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Nitrocullulose Membrane</td>
			<td>Bio-Rad</td>
			<td>1620115</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:424px;">SuperSignal West Dura Extended Duration Substrate ( chemiluminiscence substrate)</td>
			<td>Thermo Scientific</td>
			<td>34075</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD5</td>
			<td>eBioscience</td>
			<td>13-0051-82</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD11b</td>
			<td>eBioscience</td>
			<td>13-0112-75</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD45R (B220)</td>
			<td>BD biosciences</td>
			<td>553092</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD45.1-FITC</td>
			<td>eBioscience</td>
			<td>11-0453-85</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD45.2-PE</td>
			<td>eBioscience</td>
			<td>12-0454-83</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">hCD45-FITC</td>
			<td>BD Biosciences</td>
			<td>555482</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Anti-Biotin-FITC</td>
			<td>Miltenyi</td>
			<td>130-090-857&#160;</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Anti-7-4</td>
			<td>eBioscience</td>
			<td>MA5-16539</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Anti-Gr-1 (Ly-6G/c)</td>
			<td>eBioscience</td>
			<td>13-5931-82</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Anti-Ter-119</td>
			<td>eBioscience</td>
			<td>13-5921-75</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Ly-6 A/E (Sca1) PE Cy7</td>
			<td>BD&#160;</td>
			<td>558612</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD117 APC&#160;</td>
			<td>BD&#160;</td>
			<td>553356</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">BD Pharm Lyse</td>
			<td>BD&#160;</td>
			<td>555899</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">BD Cytofix/Cytoperm (Fixing and permeabilization solution)</td>
			<td>BD&#160;</td>
			<td>554714</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:424px;">BD Perm/Wash&#160; (permeabilization and wash solution for phospho flow)</td>
			<td>BD&#160;</td>
			<td>554723</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">phospho p38</td>
			<td>Cell Signaling Technologies</td>
			<td>4511S</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">total p38</td>
			<td>Cell Signaling Technologies</td>
			<td>9212</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Mouse IgG control</td>
			<td>BD&#160;</td>
			<td>554121</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Alexa Flour 488 conjugated&#160;</td>
			<td>Invitrogen</td>
			<td>A-11034</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Calcium Chloride</td>
			<td>Invitrogen</td>
			<td>K278001</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">2X HBS</td>
			<td>Invitrogen</td>
			<td>K278002</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">EDTA</td>
			<td>Ambion</td>
			<td>AM9261</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">BSA</td>
			<td>Sigma</td>
			<td>A7906</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Blood Capillary Tubes</td>
			<td>Fisher</td>
			<td>22-260-950</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Blood Collection Tube</td>
			<td>Giene Bio-One</td>
			<td>450480</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Newborn Calf Serum</td>
			<td>Atlanta biological</td>
			<td>S11295</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Erythropoiein</td>
			<td>Amgen</td>
			<td>5513-267-10</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">human SCF</td>
			<td>Prospec</td>
			<td>CYT-255</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Human IL-3</td>
			<td>Prospec</td>
			<td>CYT-210</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">G-SCF</td>
			<td>Prospec</td>
			<td>CYT-220</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">GM-CSF</td>
			<td>Prospec</td>
			<td>CYT-221</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">MyeloCult (media for LTCIC assay)</td>
			<td>Stem Cell Technologies</td>
			<td>5100</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Hydrocortisone Sodium Hemisuccinate</td>
			<td>Stem Cell Technologies</td>
			<td>7904</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">MEM alpha</td>
			<td>Gibco</td>
			<td>12561-056</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">1/2cc Lo-Dose u-100 insulin syringe 28 G1/2</td>
			<td>Becton Dickinson</td>
			<td>329461</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Mortor pestle</td>
			<td>Coor tek&#160;</td>
			<td>60316 and 60317</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Isoflorane (Isothesia TM)</td>
			<td>Butler Schien</td>
			<td>29405</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">SOC</td>
			<td>New England Biolabs</td>
			<td>B90920s</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Ampicillin</td>
			<td>Sigma</td>
			<td>A0166</td>
			<td style="width:131px;">100mg/ml stock in water</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Bacto agar (agar)</td>
			<td>Difco</td>
			<td>214050</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Terrific broth</td>
			<td>Becton Dickinson</td>
			<td>243820</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Agarose</td>
			<td>Genemate</td>
			<td>E-3119-500</td>
			<td></td>
		</tr>
		<tr height="105">
			<td height="105" style="height:105px;">Doxycycline chow</td>
			<td>TestDiet.com</td>
			<td>52662</td>
			<td style="width:131px;">modified RMH1500, Autoclavable 5LK8&#160; with 0.0625% Doxycycline&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Tamoxifen</td>
			<td>Sigma</td>
			<td>T5648</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Iodonitrotetrazolium chloride&#160;</td>
			<td>Sigma</td>
			<td>I10406</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Kits</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Dneasy Blood &#38; tissue kit</td>
			<td>Qiagen</td>
			<td>69506</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">GoTaq Green (taq polymerase with Green loadign dye)</td>
			<td>Promega</td>
			<td>M1722</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">miRNeasy Mini Kit&#160; (RNA isolation kit)</td>
			<td>Qiagen</td>
			<td>217084</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DNA Free Dnase Kit (DNAse treatment for RT PCR)</td>
			<td>Ambion, Life Technologies</td>
			<td>AM1906</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:424px;">Superscript III First Strand Synthesis (reverse transcriptase for cDNA synthesis)</td>
			<td>Invitrogen</td>
			<td>18080051</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:424px;">SYBR Green (taq polymerase mix with green interchalating dye for qPCR)</td>
			<td>Bio-Rad</td>
			<td>1725270</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CD117 MicroBead Kit</td>
			<td>Miltenyi</td>
			<td>130-091-224</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Human Long-Term Culture Initiating Cell Assay</td>
			<td>Stemp Cell Technologies</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Instruments</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">NAPCO series 8000 WJ CO2 incubator</td>
			<td>Thermo scientific</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Swing bucket rotor cetrifuge 5810R</td>
			<td>Eppendorf</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">TC-10 automated cell counter</td>
			<td>Bio-RAD</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">C-1000 Thermal cycler</td>
			<td>Bio-RAD</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Mastercycler Real Plex 2</td>
			<td>Eppendorf</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:424px;">ChemiDoc Imaging System (imaging system for gels and western blots)</td>
			<td>Bio-RAD</td>
			<td>17001401</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Hemavet ( boold counter)</td>
			<td>Drew-Scientific</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">LSR II ( FACS analyzer)</td>
			<td>BD&#160;</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Fortessa I ( FACS analyzer)</td>
			<td>BD&#160;</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">FACSAriaII ( FACS Sorter)</td>
			<td>BD&#160;</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Magnet Stand</td>
			<td>Miltenyi</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Irradiator</td>
			<td style="width:247px;">&#160;J.L. Shepherd and Associates, San Fernando CA</td>
			<td>Mark I Model 68A</td>
			<td>source Cs 137</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Mice</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">ROSACreERT2</td>
			<td>Jackson Laboratory</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Scl-tTA&#160;</td>
			<td>Dr. Claudia Huettner&#8217;s lab</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">BoyJ&#160;</td>
			<td>mouse core facility at CCHMC</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">C57Bl/6&#160;</td>
			<td>Jackson Laboratory</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">NSGS</td>
			<td>mouse core facility at CCHMC</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="24">
			<td height="24" style="height:24px;">ROSACreERT2/c-Fosfl/fl Dusp1-/-&#160;</td>
			<td>Made in house</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">ROSACreERT2/c-Fosfl/fl</td>
			<td>Made in house</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Cells</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">BaF3</td>
			<td style="width:247px;">Gift from George Daley, Harvard Medical School, Boston</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">WEHI</td>
			<td style="width:247px;">Gift from George Daley, Harvard Medical School, Boston</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">CML-CD34+ and Normal CD34+ cells</td>
			<td style="width:247px;">University Hospital, University of Cincinnati</td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

methods for evaluating the role of c-fos and dusp1 in oncogene dependence

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, a small population of cells does not respond to TKI treatment, resulting in minimal residual disease (MRD); even the most potent TKIs fail to eradicate these cells. These MRD cells serve as a reservoir to develop resistance to therapy. Why TKI treatment is ineffective against MRD cells is not known. Growth factor signaling is implicated in supporting the survival of MRD cells during TKI treatment, but a mechanistic understanding is lacking. Recent studies demonstrated that an elevated c-Fos and Dusp1 expression as a result of convergent oncogenic and growth factor signaling in MRD cells mediate TKI resistance. The genetic and chemical inhibition of c-Fos and Dusp1 renders CML exquisitely sensitive to TKIs and cures CML in both genetic and humanized mouse models. We identified these target genes using multiple microarrays from TKI-sensitive and -resistant cells. Here, we provide methods for target validation using in vitro and in vivo mouse models. These methods can easily be applied to any target for genetic validation and therapeutic development.

Oncogene addiction has been implicated in the therapeutic efficacy of TKIs. However, the mechanisms driving the oncogene dependence are not understood. We performed multiple unbiased gene expression analyses to identify the genetic component involved in orchestrating the addiction. These analyses revealed the upregulation of three genes, c-Fos, Dusp1, and Zfp36, in cancer cells that are not dependent on oncogenic signaling for survival and, thus, are insensitive to TKI treatment. The down...

Watch this Scientific Journal Video about Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence at JoVE.com

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Here, we describe protocols for the genetic and chemical validation of c-Fos and Dusp1 as a drug target in leukemia using in vitro and in vivo genetic and humanized mouse models. This method can be applied to any target for genetic validation and therapeutic development.

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, ...

Research

JoVE Journal

Cancer Research

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Glioblastoma multiforme (grade IV glioma) is a very aggressive human cancer with a median survival of 1 year post diagnosis. Despite the increased ...

The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics

The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics

Drosophila melanogaster has emerged as a powerful experimental system for functional and mechanistic studies of tumor development and progression in the ...

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

DNA damage is a common phenomenon for each cell during its lifespan, and is defined as an alteration of the chemical structure of genomic DNA. Cancer ...

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome

Human pituitary adenoma (PA) is a common tumor that occurs in the human pituitary gland in the hypothalamus-pituitary-targeted organ axis systems, and may ...

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Fatigue is a common and debilitating condition that affects most cancer patients. To date, fatigue remains poorly characterized with no diagnostic test to ...

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Bladder cancer is a significant health problem. It is estimated that more than 16,000 people will die this year in the United States from bladder cancer. ...

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

The rapidly accelerated fibrosarcoma (RAF) family kinases play a central role in cell biology and their dysfunction leads to cancers and developmental ...

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

The prostate epithelium is comprised predominantly of basal and luminal cells. In vivo lineage tracing has been utilized to define the differentiation ...

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Notch signaling is a highly conserved regulatory pathway involved in many cellular processes. Dysregulation of this signaling pathway often leads to ...

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

This manuscript describes a protocol to evaluate cancer cell deaths in three dimensional (3D) spheroids of multicellular types of cancer cells using ...